Norimin 84 pack: Supply issue
Due to a delayed shipment, there may be limited stock of ethinyloestradiol with norethisterone (Norimin) 84-pack (Pharmacode 410691).
Affected product
The supplier advised that the next shipments of this product have been delayed. This may mean limited supply of Norimin from late November 2025 until late January 2026.
Ethinyloestradiol 35 mcg with norethisterone 500 mcg and 7 inert tab
- Brand: Norimin
- Pharmacode: 410691
- Price: $21.99
- Pack size: per 84
Alternate product
Pfizer sourced the Australian version of their product to cover any out of stock. This has been listed in the Pharmaceutical Schedule from 1 December 2025.
- Brand: Norimin
- Pharmacode: 2636077
- Price: $29.32
- Pack size: per 112
Schedule listing for Norimin(external link)
About Australian Norimin
It is the same medicine, made in the same factory as the New Zealand Norimin. The key difference is that it comes in a 4‑month pack, not the standard NZ 3‑month pack. The packaging has Australian contact details on it.
The blister foils are also identical (silver area containing active tablets and red area containing non-active sugar tablets). But the artwork printed on it differs.
Please use the New Zealand Medsafe Datasheet and Consumer Medicines Information sheet for sponsor, medical information, and poison centre contact details.
Norimin Datasheet | Medsafe website [PDF](external link)
Norimin Consumer Medicines Information | Medsafe website [PDF](external link)
Medsafe has given the product a labelling exemption, so it can be prescribed and dispensed as normal.
Information for pharmacies
The 84‑pack and 112‑pack are the same size and only have a small number to indicate the difference. You may want to take measures to keep the stock separated to avoid mixing them up.
Practitioners Supply Order (PSO)
We have adjusted the PSO to 112 so the Australian product can be used on PSO.
Expected resupply late January 2026
The supplier expects to return to normal supply levels by the end of January 2026.
Who to contact
If you have any questions about this, email enquiry@pharmac.govt.nz